VYNE Therapeutics (VYNE) Other Accumulated Expenses (2017 - 2025)

VYNE Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $1.3 million for Q1 2025.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $1.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.3 million (changed N/A YoY) and the FY2024 annual result came in at $1.3 million, changed N/A from the prior year.
• Other Accumulated Expenses was $1.3 million for Q1 2025 at VYNE Therapeutics, roughly flat from $1.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.3 million in Q2 2024 and bottomed at $104000.0 in Q1 2021.
• A 3-year average of $794857.1 and a median of $1.3 million in 2024 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 126.09% in 2021, while the deepest fall reached 72.77% in 2021.
• VYNE Therapeutics' Other Accumulated Expenses stood at $104000.0 in 2021, then surged by 1162.5% to $1.3 million in 2024, then changed by 0.0% to $1.3 million in 2025.
• Business Quant data shows VYNE's Other Accumulated Expenses at $1.3 million in Q1 2025, $1.3 million in Q4 2024, and $1.3 million in Q3 2024.